Vincenzo Corbo

List of Publications by Year in Descending Order

211 papers	27,781 citations	75 h-index	166 g-index
227 ext. papers	32,239 ext. citations	10.7 avg, IF	7.18 L-index

#	Paper	IF	Citations
211	Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. **2022**, 10,		3
210	Immune-guided therapy of COVID-19.. *Cancer Immunology Research*, **2022**,	12.5	2
209	Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020.. *Cancer Immunology, Immunotherapy*, **2022**, 1	7.4	
208	Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients.. *Frontiers in Immunology*, **2021**, 12, 809826	8.4	0
207	Phenotypical Characterization and Isolation of Tumor-Derived Mouse Myeloid-Derived Suppressor Cells. *Methods in Molecular Biology*, **2021**, 2236, 29-42	1.4	
206	Cell Lineage Infidelity in PDAC Progression and Therapy Resistance.. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 795251	5.7	1
205	GM-CSF Nitration Is a New Driver of Myeloid Suppressor Cell Activity in Tumors. *Frontiers in Immunology*, **2021**, 12, 718098	8.4	1
204	Deciphering the state of immune silence in fatal COVID-19 patients. *Nature Communications*, **2021**, 12, 1428	17.4	34
203	The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime. *Modern Pathology*, **2021**, 34, 1444-1455	9.8	18
202	Galectin-1 Supports a Dangerous Liaison between Monocytes and Multiple Myeloma. *Cancer Immunology Research*, **2021**, 9, 488	12.5	
201	Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data. *European Journal of Cancer*, **2021**, 148, 348-358	7.5	0
200	Molecular alterations in basal cell carcinoma subtypes. *Scientific Reports*, **2021**, 11, 13206	4.9	5
199	The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia. *Stem Cell Research and Therapy*, **2021**, 12, 316	8.3	4
198	Monocytes in the Tumor Microenvironment. *Annual Review of Pathology: Mechanisms of Disease*, **2021**, 16, 93-122	34	24
197	Covid-19 Interstitial Pneumonia: Histological and Immunohistochemical Features on Cryobiopsies. *Respiration*, **2021**, 100, 488-498	3.7	41
196	Wnt-Ecatenin as an epigenetic switcher in colonic T cells. *Nature Immunology*, **2021**, 22, 400-401	19.1	0
195	How to Reprogram Myeloma-Associated Macrophages: Target IKZF1. *Cancer Immunology Research*, **2021**, 9, 254	12.5	0

194	Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade. *Cancer Immunology Research*, **2021**, 9, 1316-1326	12.5	5
193	Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. *Cell Death and Differentiation*, **2021**,	12.7	4
192	Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 308	5.7	5
191	Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy. *Science Translational Medicine*, **2020**, 12,	17.5	14
190	Increased Arginase1 expression in tumor microenvironment promotes mammary carcinogenesis via multiple mechanisms. *Carcinogenesis*, **2020**, 41, 1695-1702	4.6	0
189	Generation of Pancreatic Organoid-Derived Isografts. *STAR Protocols*, **2020**, 1, 100047	1.4	1
188	Macrophages Instruct Aberrant Glycosylation in Colon Cancer by Chemokine and Cytokine Signals. *Cancer Immunology Research*, **2020**, 8, 160	12.5	2
187	Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules. *Journal of Nanobiotechnology*, **2020**, 18, 31	9.4	16
186	Detection and functional evaluation of arginase-1 isolated from human PMNs and murine MDSC. *Methods in Enzymology*, **2020**, 632, 193-213	1.7	5
185	Baricitinib restrains the immune dysregulation in patients with severe COVID-19. *Journal of Clinical Investigation*, **2020**, 130, 6409-6416	15.9	130
184	Complete neural stem cell (NSC) neuronal differentiation requires a branched chain amino acids-induced persistent metabolic shift towards energy metabolism. *Pharmacological Research*, **2020**, 158, 104863	10.2	14
183	Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 2975-2989	9.4	76
182	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. *Cytotherapy*, **2020**, 22, 474-481	4.8	21
181	Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages. *Cancer Discovery*, **2020**, 10, 1758-1773	24.4	17
180	Oncolytic virotherapy meets the human organoid technology for pancreatic cancers. *EBioMedicine*, **2020**, 57, 102828	8.8	
179	Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
178	Tumor-Derived Prostaglandin E2 Promotes p50 NF-B-Dependent Differentiation of Monocytic MDSCs. *Cancer Research*, **2020**, 80, 2874-2888	10.1	42
177	Modeling Cell Communication in Cancer With Organoids: Making the Complex Simple. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 166	5.7	38

176	The Endless Saga of Monocyte Diversity. *Frontiers in Immunology*, **2019**, 10, 1786	8.4	36
175	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. *Cell Research*, **2019**, 29, 846-861	24.7	91
174	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. *Blood*, **2019**, 134, 1670-1682	2.2	33
173	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 **2019**, 7, 255		81
172	Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report. *Clinical Lung Cancer*, **2019**, 20, e514-e516	4.9	6
171	Deciphering Macrophage and Monocyte Code to Stratify Human Breast Cancer Patients. *Cancer Cell* , **2019**, 35, 538-539	24.3	8
170	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. *Cancers*, **2019**, 11,	6.6	47
169	Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. *Scientific Reports*, **2019**, 9, 12286	4.9	15
168	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. *Cancer Research*, **2019**, 79, 4715-4728	10.1	51
167	Close to the Bone: Tissue-Specific Checkpoint Immunotherapy Evasion. *Cell*, **2019**, 179, 1010-1012	56.2	
166	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. *Cancer Research*, **2019**, 79, 1938-1951	10.1	33
165	GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. *Science Immunology*, **2019**, 4,	28	34
164	Co-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells. *Journal of Controlled Release*, **2019**, 295, 60-73	11.7	23
163	Peripheral blood immunophenotyping in a large cohort of patients with Shwachman-Diamond syndrome. *Pediatric Blood and Cancer*, **2019**, 66, e27597	3	3
162	Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo. *Current Protocols in Immunology*, **2019**, 124, e61	4	20
161	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6cCD103 Monocytic Antigen-Presenting Cells in Tumors. *Immunity*, **2018**, 48, 91-106.e6	32.3	63
160	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. *Carcinogenesis*, **2018**, 39, 971-980	4.6	32
159	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. *Journal of Experimental and Clinical Cancer Research*, **2018**, 37, 140	12.8	22

158	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. *Human Pathology*, **2018**, 81, 157-165	3.7	23
157	The expanding constellation of immune checkpoints: a DNAMic control by CD155. *Journal of Clinical Investigation*, **2018**, 128, 2199-2201	15.9	5
156	Induction of immunosuppressive functions and NF-B by FLIP in monocytes. *Nature Communications*, **2018**, 9, 5193	17.4	31
155	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. *Pathology Research and Practice*, **2018**, 214, 1675-1680	3.4	1
154	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. *Scientific Reports*, **2017**, 7, 43013	4.9	36
153	Bone marrow mesenchymal stromal cells induce nitric oxide synthase-dependent differentiation of CD11b cells that expedite hematopoietic recovery. *Haematologica*, **2017**, 102, 818-825	6.6	12
152	A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells. *Immunity*, **2017**, 46, 233-244	32.3	154
151	4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells. *Journal of Immunology*, **2017**, 198, 4166-4177	5.3	20
150	The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. *Current Opinion in Pharmacology*, **2017**, 35, 30-39	5.1	79
149	Fhit down-regulation is an early event in pancreatic carcinogenesis. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2017**, 470, 647-653	5.1	4
148	From Oncogene Interference to Neutrophil Immune Modulation. *Immunity*, **2017**, 47, 613-615	32.3	
147	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy **2017**, 5, 44		139
146	Hypermutation In Pancreatic Cancer. *Gastroenterology*, **2017**, 152, 68-74.e2	13.3	130
145	Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. *Oncotarget*, **2017**, 8, 86987-87001	3.3	13
144	Adipocytes and Neutrophils Give a Helping Hand to Pancreatic Cancers. *Cancer Discovery*, **2016**, 6, 821-3	24.4	5
143	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nature Communications*, **2016**, 7, 12150	17.4	1388
142	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. *Cancer Immunology, Immunotherapy*, **2016**, 65, 161-9	7.4	140
141	Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. *Seminars in Immunology*, **2016**, 28, 54-63	10.7	31

140	Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature*, **2016**, 531, 47-52	50.4	1785
139	MDSCs in cancer: Conceiving new prognostic and therapeutic targets. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2016**, 1865, 35-48	11.2	51
138	Immune suppressive mechanisms in the tumor microenvironment. *Current Opinion in Immunology*, **2016**, 39, 1-6	7.8	305
137	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. *Targeted Oncology*, **2016**, 11, 345-51	5	48
136	Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo". *Oncotarget*, **2016**, 7, 74189-74202	3.3	11
135	Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. *Oncotarget*, **2016**, 7, 1168-84	3.3	82
134	Tumor-Induced Myeloid-Derived Suppressor Cells. *Microbiology Spectrum*, **2016**, 4,	8.9	21
133	Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. *Cancer Research*, **2016**, 76, 2540-51	10.1	21
132	Interfering with CCL5/CCR5 at the Tumor-Stroma Interface. *Cancer Cell*, **2016**, 29, 437-439	24.3	14
131	Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. *Biomaterials*, **2016**, 96, 47-62	15.6	98
130	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. *Cancer Cell*, **2016**, 30, 377-390	24.3	93
129	Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. *Current Opinion in Immunology*, **2015**, 33, 120-5	7.8	44
128	Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210. *Cancer Research*, **2015**, 75, 3771-87	10.1	84
127	Monocyte-Derived Suppressor Cells in Transplantation. *Current Transplantation Reports*, **2015**, 2, 176-183	1.5	23
126	CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells. *Journal of Immunology*, **2015**, 195, 3482-9	5.3	20
125	Transgenic mice overexpressing arginase 1 in monocytic cell lineage are affected by lympho-myeloproliferative disorders and disseminated intravascular coagulation. *Carcinogenesis*, **2015**, 36, 1354-62	4.6	2
124	Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. *Immunology*, **2015**, 146, 33-49	7.8	5
123	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. *Blood*, **2015**, 126, 1621-8	2.2	82

122	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. *PLoS ONE*, **2015**, 10, e0130142	3.7	339
121	DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance. *Immunity*, **2015**, 42, 1143-58	32.3	105
120	Complexity and challenges in defining myeloid-derived suppressor cells. *Cytometry Part B - Clinical Cytometry*, **2015**, 88, 77-91	3.4	86
119	Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer. *Nature Medicine*, **2015**, 21, 117-9	50.5	92
118	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. *Journal of Clinical Investigation*, **2015**, 125, 3365-76	15.9	351
117	Critical role of gap junction communication, calcium and nitric oxide signaling in bystander responses to focal photodynamic injury. *Oncotarget*, **2015**, 6, 10161-74	3.3	28
116	PD-L1 is a novel direct target of HIF-1□and its blockade under hypoxia enhanced MDSC-mediated T cell activation. *Journal of Experimental Medicine*, **2014**, 211, 781-90	16.6	1136
115	Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. *Journal of Virology*, **2014**, 88, 3612-22	6.6	76
114	Tumors STING adaptive antitumor immunity. *Immunity*, **2014**, 41, 679-81	32.3	13
113	Myeloid-derived suppressor cell heterogeneity in human cancers. *Annals of the New York Academy of Sciences*, **2014**, 1319, 47-65	6.5	280
112	Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. *European Journal of Immunology*, **2014**, 44, 3307-19	6.1	81
111	Differential control of Mincle-dependent cord factor recognition and macrophage responses by the transcription factors C/EBP□and HIF1□*Journal of Immunology*, **2014**, 193, 3664-75	5.3	44
110	Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. *Biomatter*, **2014**, 4, e955386		32
109	Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs). *Genomics Data*, **2014**, 2, 389-92		8
108	ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. *Cell Death and Disease*, **2014**, 5, e1135	9.8	83
107	Tumor cells hijack macrophages via lactic acid. *Immunology and Cell Biology*, **2014**, 92, 647-9	5	27
106	Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. *Immunity*, **2014**, 41, 947-59	32.3	101
105	Complexity and challenges in defining myeloid-derived suppressor cells. *Cytometry Part B - Clinical Cytometry*, **2014**,	3.4	82

104	The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. *Frontiers in Immunology*, **2014**, 5, 69	8.4	48
103	Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic Approaches. *Advances in Delivery Science and Technology*, **2014**, 187-214		
102	Myeloid-Derived Suppressor Cells in Tumor-Induced T Cell Suppression and Tolerance **2014**, 99-150		2
101	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation **2013**, 597-634		2
100	The spleen in local and systemic regulation of immunity. *Immunity*, **2013**, 39, 806-18	32.3	477
99	miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. *Immunity*, **2013**, 38, 1236-49	32.3	108
98	Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. *Cell Host and Microbe*, **2013**, 13, 155-68	23.4	50
97	High-avidity T cells are preferentially tolerized in the tumor microenvironment. *Cancer Research*, **2013**, 73, 595-604	10.1	33
96	Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. *Blood*, **2013**, 121, 1740-8	2.2	21
95	Coordinated regulation of myeloid cells by tumours. *Nature Reviews Immunology*, **2012**, 12, 253-68	36.5	2405
94	The pros and cons of chemokines in tumor immunology. *Trends in Immunology*, **2012**, 33, 496-504	14.4	80
93	Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. *Cell Reports* , **2012**, 2, 628-39	10.6	152
92	Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells. *Neoplasia*, **2012**, 14, 1236-48	6.4	23
91	Nitric oxide affects immune cells bioenergetics: long-term effects of nitric-oxide derivatives on leukaemic Jurkat cell metabolism. *Immunobiology*, **2012**, 217, 808-15	3.4	3
90	L-glutamine is a key parameter in the immunosuppression phenomenon. *Biochemical and Biophysical Research Communications*, **2012**, 425, 724-9	3.4	30
89	Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. *BMC Cell Biology*, **2012**, 13, 18		44
88	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. *Nature Medicine*, **2012**, 18, 1254-61	50.5	636
87	Smoothing T cell roads to the tumor: Chemokine post-translational regulation. *OncoImmunology*, **2012**, 1, 390-392	7.2	5

86	Myeloid-derived suppressor cells in cancer patients: a clinical perspective. *Journal of Immunotherapy*, **2012**, 35, 107-15	5	176
85	Myeloid-Derived Suppressor Cells in Cancer **2012**, 217-229		
84	Antigen specificity of immune suppression by myeloid-derived suppressor cells. *Journal of Leukocyte Biology*, **2011**, 90, 31-6	6.5	67
83	Tumour-Induced Immune Suppression by Myeloid Cells **2011**, 49-62		
82	In vivo induction of myeloid suppressor cells and CD4(+)Foxp3(+) T regulatory cells prolongs skin allograft survival in mice. *Cell Transplantation*, **2011**, 20, 941-54	4	57
81	Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. *Blood*, **2011**, 117, 7053-62	2.2	176
80	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. *Blood*, **2011**, 118, 2254-65	2.2	280
79	Myeloid cell diversification and complexity: an old concept with new turns in oncology. *Cancer and Metastasis Reviews*, **2011**, 30, 27-43	9.6	34
78	Modulation of human T-cell functions by reactive nitrogen species. *European Journal of Immunology* , **2011**, 41, 1843-9	6.1	50
77	Transcription factors in myeloid-derived suppressor cell recruitment and function. *Current Opinion in Immunology*, **2011**, 23, 279-85	7.8	53
76	Myeloid-derived suppressor cells exhibit two bioenergetic steady-states in vitro. *Journal of Biotechnology*, **2011**, 152, 43-8	3.7	5
75	Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. *Journal of Leukocyte Biology*, **2011**, 89, 721-7	6.5	86
74	Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. *Journal of Immunology*, **2011**, 186, 264-74	5.3	46
73	Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *Journal of Experimental Medicine*, **2011**, 208, 1949-62	16.6	455
72	Tolerogenic pDCs: spotlight on Foxo3. *Journal of Clinical Investigation*, **2011**, 121, 1247-50	15.9	7
71	Control of immune response by amino acid metabolism. *Immunological Reviews*, **2010**, 236, 243-64	11.3	196
70	The transcriptional response in human umbilical vein endothelial cells exposed to insulin: a dynamic gene expression approach. *PLoS ONE*, **2010**, 5, e14390	3.7	6
69	MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. *Endocrine-Related Cancer*, **2010**, 17, 771-83	5.7	110

68	Role of microRNAs in HTLV-1 infection and transformation. *Molecular Aspects of Medicine*, **2010**, 31, 367-82	12.7	32
67	IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. *Vaccine*, **2010**, 28, 3548-57	4.1	75
66	Measurement of myeloid cell immune suppressive activity. *Current Protocols in Immunology*, **2010**, Chapter 14, Unit 14.17	4	15
65	Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. *European Journal of Immunology*, **2010**, 40, 22-35	6.1	406
64	Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. *Blood*, **2010**, 115, 1374-84	2.2	27
63	Myeloid-derived suppressor cell heterogeneity and subset definition. *Current Opinion in Immunology*, **2010**, 22, 238-44	7.8	520
62	Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. *Immunity*, **2010**, 32, 790-802	32.3	644
61	Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. *Carcinogenesis*, **2009**, 30, 851-60	4.6	25
60	In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. *Cancer Research*, **2009**, 69, 9376-84	10.1	50
59	Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. *European Journal of Immunology*, **2009**, 39, 56-66	6.1	23
58	Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. *European Journal of Immunology*, **2009**, 39, 2670-2	6.1	111
57	Therapeutic targeting of myeloid-derived suppressor cells. *Current Opinion in Pharmacology*, **2009**, 9, 470-81	5.1	169
56	IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. *Journal of Immunology*, **2009**, 182, 6562-8	5.3	263
55	Suppressive influences in the immune response to cancer. *Journal of Immunotherapy*, **2009**, 32, 1-11	5	62
54	Myeloid-derived suppressor cell role in tumor-related inflammation. *Cancer Letters*, **2008**, 267, 216-25	9.9	96
53	Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. *Cancer Research*, **2008**, 68, 9865-74	10.1	40
52	Th17 and cancer: friends or foes?. *Blood*, **2008**, 112, 214	2.2	28
51	Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. *Immunological Reviews*, **2008**, 222, 162-79	11.3	508

50	Myeloid-Derived Suppressor Cells in Cancer **2008**, 157-195		2
49	Role of arginine metabolism in immunity and immunopathology. *Immunobiology*, **2007**, 212, 795-812	3.4	114
48	Altered macrophage differentiation and immune dysfunction in tumor development. *Journal of Clinical Investigation*, **2007**, 117, 1155-66	15.9	899
47	Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. *Medicinal Research Reviews*, **2007**, 27, 317-52	14.4	351
46	The terminology issue for myeloid-derived suppressor cells. *Cancer Research*, **2007**, 67, 425; author reply 426	10.1	519
45	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-Arginine Metabolism in Immune Modulation **2007**, 369-399		
44	Metabolic mechanisms of cancer-induced inhibition of immune responses. *Seminars in Cancer Biology*, **2007**, 17, 309-16	12.7	30
43	Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. *Thyroid*, **2007**, 17, 1109-15	6.2	81
42	Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. *Seminars in Cancer Biology*, **2006**, 16, 53-65	12.7	615
41	Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. *Journal of Experimental Medicine*, **2006**, 203, 2691-702	16.6	588
40	Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. *Immunological Investigations*, **2006**, 35, 327-57	2.9	32
39	Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. *Blood*, **2006**, 107, 2846-54	2.2	166
38	Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. *Journal of Clinical Investigation*, **2006**, 116, 2777-90	15.9	637
37	Cancer immunotherapy based on killing of Salmonella-infected tumor cells. *Cancer Research*, **2005**, 65, 3920-7	10.1	125
36	Cancer rejection by the immune system: Forcing the check-points of tumor immune escape. *Drug Discovery Today Disease Mechanisms*, **2005**, 2, 191-197		1
35	Regulation of immune responses by L-arginine metabolism. *Nature Reviews Immunology*, **2005**, 5, 641-54	36.5	1294
34	Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. *Journal of Experimental Medicine*, **2005**, 201, 1257-68	16.6	311
33	Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 4185-90	11.5	253

32	High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. *Cancer Research*, **2004**, 64, 6337-43	10.1	420
31	Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes. *Cancer Research*, **2004**, 64, 8068-76	10.1	22
30	Cancer vaccines: pessimism in check. *Nature Medicine*, **2004**, 10, 1278-9; author reply 1279-80	50.5	40
29	Derangement of immune responses by myeloid suppressor cells. *Cancer Immunology, Immunotherapy*, **2004**, 53, 64-72	7.4	294
28	CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response. *Cancer Immunology, Immunotherapy*, **2004**, 53, 697-704	7.4	6
27	Part I: Vaccines for solid tumours. *Lancet Oncology, The*, **2004**, 5, 681-9	21.7	180
26	IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. *Journal of Immunology*, **2003**, 170, 270-8	5.3	400
25	Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. *Journal of Immunology*, **2003**, 171, 6396-405	5.3	32
24	Methotrexate for immunosuppression in life-supporting pig-to-cynomolgus monkey renal xenotransplantation. *Xenotransplantation*, **2003**, 10, 587-95	2.8	14
23	L-arginine metabolism in myeloid cells controls T-lymphocyte functions. *Trends in Immunology*, **2003**, 24, 302-6	14.4	421
22	Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. *Journal of Immunology*, **2002**, 168, 689-95	5.3	506
21	Genetic vaccination for the active immunotherapy of cancer. *Current Gene Therapy*, **2001**, 1, 53-100	4.3	19
20	Tumor-induced immune dysfunctions caused by myeloid suppressor cells. *Journal of Immunotherapy*, **2001**, 24, 431-46	5	214
19	Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. *Blood*, **2000**, 96, 3838-3846	2.2	442
18	Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. *Journal of Immunology*, **2000**, 165, 6723-30	5.3	136
17	Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. *Blood*, **2000**, 96, 3838-3846	2.2	54
16	Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. *Journal of Immunotherapy*, **1999**, 22, 489-96	5	35
15	Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 3183-8	11.5	136

14	Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5Ptriphosphate. *Biochemical and Biophysical Research Communications*, **1996**, 218, 344-51	3.4	34
13	Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. *Journal of Immunotherapy*, **1995**, 18, 139-46	5	23
12	Molecular genetics of cancer. Gene therapy and other novel therapeutic approaches. *Cancer*, **1995**, 76, 1878-81	6.4	1
11	Role of anti-LFA-1 and anti-ICAM-1 combined MAb treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV). *International Journal of Cancer*, **1995**, 61, 355-62	7.5	7
10	Role of extracellular ATP in cell-mediated cytotoxicity: a study with ATP-sensitive and ATP-resistant macrophages. *Cellular Immunology*, **1994**, 156, 458-67	4.4	25
9	Inhibition of protein tyrosine phosphorylation prevents T-cell-mediated cytotoxicity. *Cellular Immunology*, **1994**, 159, 294-305	4.4	10
8	Synergistic effect of extracellular adenosine 5Ptriphosphate and tumor necrosis factor on DNA degradation. *Cellular Immunology*, **1993**, 152, 110-9	4.4	9
7	Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. *Cancer Immunology, Immunotherapy*, **1992**, 35, 27-32	7.4	6
6	Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. *Trends in Immunology*, **1990**, 11, 274-7		104
5	Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity. *Cellular Immunology*, **1989**, 122, 450-60	4.4	7
4	Tumor-Induced Myeloid-Derived Suppressor Cells833-856		1
3	Baricitinib restrains the immune dysregulation in COVID-19 patients		8
2	Deciphering the state of immune silence in fatal COVID-19 patients		4
1	Ursula Grohmann, PhD: In Memoriam (1961–2022). *Cancer Immunology Research*,OF1-OF1	12.5	